标准三联疗法与左氧氟沙星替代疗法治疗幽门螺杆菌感染的疗效比较

2018-10-23 小月 医学论坛网

目的: 评价克拉霉素标准三联疗法与左氧氟沙星一线治疗幽门螺杆菌感染的疗效。


目的:

评价克拉霉素标准三联疗法与左氧氟沙星一线治疗幽门螺杆菌感染的疗效。

方法:

本前瞻性观察研究于2016年5月至2017年5月31日在拉合尔阿赫特萨伊德信托教学医院进行,所有幽门螺旋杆菌阳性患者均经镜活检证实;符合本研究的纳入标准。患者分为两组(A组和B组),A组给予克拉霉素500mg,阿莫西林1g,奥美拉唑20mg,每日两次,持续两周。在B组中,左氧氟沙星用克拉霉素代替250mg,而药物的残留保持不变。患者在第1周末、第2周末和治疗结束时进行随访,记录任何不良反应和治愈率。数据采用SPSS 24.0版和MINITAB V.16进行分析。

结果:

在300名入组患者(每组150人)中,A组治愈123人(87.85%),B组治愈134人(92.4%),两种治疗方案在人群中的疗效几乎相同,结果无统计学差异。与标准的三联疗法相比,左氧氟沙星患者的不良反应明显减少。

结论:

标准三联疗法和交替三联疗法的疗效均令人满意,可用于本地区的治疗。左氧氟沙星替代治疗对患者更安全。它可用于标准治疗引起的不良反应难以忍受的情况。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1811771, encodeId=528f1811e71a9, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Jul 12 13:05:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648368, encodeId=6e5d16483685a, content=<a href='/topic/show?id=1b88603298d' target=_blank style='color:#2F92EE;'>#替代疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60329, encryptionId=1b88603298d, topicName=替代疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f1023558367, createdName=skhzy, createdTime=Thu Dec 27 16:05:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348725, encodeId=043b1348e25ec, content=<a href='/topic/show?id=cfeb49103af' target=_blank style='color:#2F92EE;'>#幽门螺杆菌感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49103, encryptionId=cfeb49103af, topicName=幽门螺杆菌感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Oct 25 13:05:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530100, encodeId=09131530100a1, content=<a href='/topic/show?id=7f7848124f5' target=_blank style='color:#2F92EE;'>#左氧氟沙星#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48124, encryptionId=7f7848124f5, topicName=左氧氟沙星)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=666412016730, createdName=cqlidoudou, createdTime=Thu Oct 25 13:05:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613710, encodeId=caa91613e10ef, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Thu Oct 25 13:05:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031946, encodeId=00881031946c2, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Oct 24 01:05:00 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
    2019-07-12 kcb069
  2. [GetPortalCommentsPageByObjectIdResponse(id=1811771, encodeId=528f1811e71a9, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Jul 12 13:05:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648368, encodeId=6e5d16483685a, content=<a href='/topic/show?id=1b88603298d' target=_blank style='color:#2F92EE;'>#替代疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60329, encryptionId=1b88603298d, topicName=替代疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f1023558367, createdName=skhzy, createdTime=Thu Dec 27 16:05:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348725, encodeId=043b1348e25ec, content=<a href='/topic/show?id=cfeb49103af' target=_blank style='color:#2F92EE;'>#幽门螺杆菌感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49103, encryptionId=cfeb49103af, topicName=幽门螺杆菌感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Oct 25 13:05:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530100, encodeId=09131530100a1, content=<a href='/topic/show?id=7f7848124f5' target=_blank style='color:#2F92EE;'>#左氧氟沙星#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48124, encryptionId=7f7848124f5, topicName=左氧氟沙星)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=666412016730, createdName=cqlidoudou, createdTime=Thu Oct 25 13:05:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613710, encodeId=caa91613e10ef, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Thu Oct 25 13:05:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031946, encodeId=00881031946c2, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Oct 24 01:05:00 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1811771, encodeId=528f1811e71a9, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Jul 12 13:05:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648368, encodeId=6e5d16483685a, content=<a href='/topic/show?id=1b88603298d' target=_blank style='color:#2F92EE;'>#替代疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60329, encryptionId=1b88603298d, topicName=替代疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f1023558367, createdName=skhzy, createdTime=Thu Dec 27 16:05:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348725, encodeId=043b1348e25ec, content=<a href='/topic/show?id=cfeb49103af' target=_blank style='color:#2F92EE;'>#幽门螺杆菌感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49103, encryptionId=cfeb49103af, topicName=幽门螺杆菌感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Oct 25 13:05:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530100, encodeId=09131530100a1, content=<a href='/topic/show?id=7f7848124f5' target=_blank style='color:#2F92EE;'>#左氧氟沙星#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48124, encryptionId=7f7848124f5, topicName=左氧氟沙星)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=666412016730, createdName=cqlidoudou, createdTime=Thu Oct 25 13:05:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613710, encodeId=caa91613e10ef, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Thu Oct 25 13:05:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031946, encodeId=00881031946c2, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Oct 24 01:05:00 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1811771, encodeId=528f1811e71a9, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Jul 12 13:05:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648368, encodeId=6e5d16483685a, content=<a href='/topic/show?id=1b88603298d' target=_blank style='color:#2F92EE;'>#替代疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60329, encryptionId=1b88603298d, topicName=替代疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f1023558367, createdName=skhzy, createdTime=Thu Dec 27 16:05:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348725, encodeId=043b1348e25ec, content=<a href='/topic/show?id=cfeb49103af' target=_blank style='color:#2F92EE;'>#幽门螺杆菌感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49103, encryptionId=cfeb49103af, topicName=幽门螺杆菌感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Oct 25 13:05:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530100, encodeId=09131530100a1, content=<a href='/topic/show?id=7f7848124f5' target=_blank style='color:#2F92EE;'>#左氧氟沙星#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48124, encryptionId=7f7848124f5, topicName=左氧氟沙星)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=666412016730, createdName=cqlidoudou, createdTime=Thu Oct 25 13:05:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613710, encodeId=caa91613e10ef, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Thu Oct 25 13:05:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031946, encodeId=00881031946c2, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Oct 24 01:05:00 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1811771, encodeId=528f1811e71a9, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Jul 12 13:05:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648368, encodeId=6e5d16483685a, content=<a href='/topic/show?id=1b88603298d' target=_blank style='color:#2F92EE;'>#替代疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60329, encryptionId=1b88603298d, topicName=替代疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f1023558367, createdName=skhzy, createdTime=Thu Dec 27 16:05:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348725, encodeId=043b1348e25ec, content=<a href='/topic/show?id=cfeb49103af' target=_blank style='color:#2F92EE;'>#幽门螺杆菌感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49103, encryptionId=cfeb49103af, topicName=幽门螺杆菌感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Oct 25 13:05:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530100, encodeId=09131530100a1, content=<a href='/topic/show?id=7f7848124f5' target=_blank style='color:#2F92EE;'>#左氧氟沙星#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48124, encryptionId=7f7848124f5, topicName=左氧氟沙星)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=666412016730, createdName=cqlidoudou, createdTime=Thu Oct 25 13:05:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613710, encodeId=caa91613e10ef, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Thu Oct 25 13:05:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031946, encodeId=00881031946c2, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Oct 24 01:05:00 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1811771, encodeId=528f1811e71a9, content=<a href='/topic/show?id=751f8889423' target=_blank style='color:#2F92EE;'>#螺杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88894, encryptionId=751f8889423, topicName=螺杆菌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87b1109, createdName=kcb069, createdTime=Fri Jul 12 13:05:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648368, encodeId=6e5d16483685a, content=<a href='/topic/show?id=1b88603298d' target=_blank style='color:#2F92EE;'>#替代疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60329, encryptionId=1b88603298d, topicName=替代疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f1023558367, createdName=skhzy, createdTime=Thu Dec 27 16:05:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348725, encodeId=043b1348e25ec, content=<a href='/topic/show?id=cfeb49103af' target=_blank style='color:#2F92EE;'>#幽门螺杆菌感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49103, encryptionId=cfeb49103af, topicName=幽门螺杆菌感染)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Thu Oct 25 13:05:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530100, encodeId=09131530100a1, content=<a href='/topic/show?id=7f7848124f5' target=_blank style='color:#2F92EE;'>#左氧氟沙星#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48124, encryptionId=7f7848124f5, topicName=左氧氟沙星)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=666412016730, createdName=cqlidoudou, createdTime=Thu Oct 25 13:05:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1613710, encodeId=caa91613e10ef, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19790, encryptionId=a59419e9059, topicName=三联疗法)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552519418574, createdName=12498636m55(暂无昵称), createdTime=Thu Oct 25 13:05:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031946, encodeId=00881031946c2, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Oct 24 01:05:00 CST 2018, time=2018-10-24, status=1, ipAttribution=)]
    2018-10-24 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

EASL 2014:FDV+DBV+ PPI-668的三联疗法可获得较高SVR率

Faldaprevir(FDV)为NS3/4A抑制剂,deleobuvir(DBV)为NS5B抑制剂,PPI-668为NS5A抑制剂。来自美国加州的研究人员使用上述药物对HCV1a型初治患者进行了为期12周的临床2期试验。该研究结果公布于2014年4月11日在伦敦举行的EASL2014会上。 该研究共纳入了36例患者。其中24例被随机分配到队列1或2中(FDV120mg QD,PPI-668 20

Lancet:治疗幽门螺杆菌,哪家强?

研究目的:比较10天伴同疗法、10天铋四联疗法、14天三联疗法,治疗幽门螺杆菌感染的有效性和安全性。 纳入年龄> 20岁的幽门螺杆菌感染患者,按1:1:1随机分为10天伴同疗法组(兰索拉唑30 mg,阿莫西林1 g,克拉霉素500 mg,甲硝唑500 mg,均每日两次)、10天铋四联疗法(钾枸橼酸铋 300 mg,每天四次,兰索拉唑 30 mg,每日两次,四环素 500 mg,每日四次

Lancet:单次吸入超细三联疗法与长效毒蕈碱受体拮抗剂治疗慢性阻塞性肺疾病哪个好?

在这个三位一体的研究中,采用超细固定三联疗法治疗有症状的COPD、FEV1小于50%且有加重病史的患者相比于噻托溴铵治疗具有临床效益。

JACC:老年房颤患者急性心肌梗死的三联疗法的应用及疗效

    抗血栓治疗对于经皮冠状动脉介入治疗(PCI)治疗的风险较高的心房颤动(AF)老年患者的急性心肌梗死(MI)效果仍不清楚。    这项研究旨在确定适当的抗血栓治疗方法治疗通过PCI治疗房颤的急性MI患者。    研究人员对4,959例≥65岁的急性MI和AF并接受冠状动脉支架置入术(急性冠脉综合治疗及干预结果网络登记处)患者进行了研

Eur J Clin Pharmacol:益生菌联合三联疗法治疗儿童幽门螺杆菌感染

近年来,应用益生菌制剂为预防和治疗幽门螺杆菌感染提供了新的思路,研究发现益生菌可以提高三联疗法的幽门螺杆菌根除率。发表在《Eur J Clin Pharmacol》的一项研究旨在确定益生菌补充三联疗法用于儿童幽门螺杆菌根除的有效性和安全性。

Circulation:三联疗法增加PCI后房颤患者的出血风险 全新抗血栓建议怎么说?

对于经皮冠状动脉介入(PCI)支架置入的房颤患者,寻找最佳抗血栓治疗方案是临床实践中的一个挑战。接受PCI的房颤患者理论上需要口服抗凝治疗联合双重抗血小板治疗(阿司匹林和P2Y12抑制剂)。该疗法也被称为三联疗法,能有效降低心源性栓塞和冠状动脉血栓并发症的风险。